HK Stock MarketDetailed Quotes

02487 CUTIA-B

Watchlist
  • 7.560
  • -0.280-3.57%
Market Closed Dec 4 16:08 CST
2.41BMarket Cap-4193P/E (TTM)

CUTIA-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
Turnover
178.30%95.58M
1,110.83%137.62M
5,119.30%34.34M
457.70%11.37M
313.84%658K
--2.04M
--159K
----
Operating income
178.30%95.58M
1,110.83%137.62M
5,119.30%34.34M
457.70%11.37M
313.84%658K
2.04M
159K
Cost of sales
-245.79%-45.24M
-1,843.26%-66.62M
-6,281.95%-13.08M
-700.93%-3.43M
-120.43%-205K
---428K
---93K
----
Operating expenses
-245.79%-45.24M
-1,843.26%-66.62M
-6,281.95%-13.08M
-700.93%-3.43M
-120.43%-205K
-428K
-93K
Gross profit
136.76%50.34M
794.53%71.01M
4,593.16%21.26M
393.04%7.94M
586.36%453K
1.61M
66K
Selling expenses
-78.33%-103.49M
-479.70%-208.31M
-871.08%-58.03M
-471.11%-35.93M
-463.24%-5.98M
---6.29M
---1.06M
----
Administrative expenses
23.12%-67.6M
-85.05%-185.89M
-113.71%-87.93M
-55.15%-100.45M
-30.43%-41.15M
-131.96%-64.75M
---31.55M
---27.91M
Research and development expenses
-9.84%-99.01M
-19.34%-215.71M
-8.00%-90.14M
-63.49%-180.76M
-66.46%-83.46M
31.72%-110.56M
---50.14M
---161.93M
Revaluation surplus
----
-344.60%-1.45B
-732.67%-1.45B
-171.83%-327.1M
-397.74%-174.65M
-358.61%-120.33M
---35.09M
--46.53M
-Changes in the fair value of financial assets
----
----
----
----
----
----
---35.09M
--46.53M
-Changes in the fair value of other assets
----
-344.60%-1.45B
-732.67%-1.45B
-171.83%-327.1M
---174.65M
---120.33M
----
----
Impairment and provision
----
---752K
----
----
----
----
----
----
-Other impairment is provision
----
---752K
----
----
----
----
----
----
Special items of operating profit
-22.37%23.68M
-57.84%34.65M
-43.28%30.5M
539.37%82.19M
819.48%53.78M
66.61%-18.71M
---7.48M
---56.02M
Operating profit
88.03%-196.08M
-253.59%-1.96B
-552.82%-1.64B
-73.69%-554.11M
-100.41%-251.01M
-60.05%-319.02M
-125.25M
-199.33M
Financing cost
-182.40%-4.85M
-159.09%-4.48M
-182.24%-1.72M
-209.12%-1.73M
-261.90%-608K
6.68%-559K
---168K
---599K
Earning before tax
87.75%-200.93M
-253.30%-1.96B
-551.93%-1.64B
-73.93%-555.84M
-100.62%-251.61M
-59.85%-319.58M
-125.42M
-199.93M
After-tax profit from continuing operations
87.75%-200.93M
-253.30%-1.96B
-551.93%-1.64B
-73.93%-555.84M
-100.62%-251.61M
-59.85%-319.58M
-125.42M
-199.93M
Earning after tax
87.75%-200.93M
-253.30%-1.96B
-551.93%-1.64B
-73.93%-555.84M
-100.62%-251.61M
-59.85%-319.58M
-125.42M
-199.93M
Minority profit
----
----
----
----
----
----
----
---29.82M
Profit attributable to shareholders
87.75%-200.93M
-253.30%-1.96B
-551.93%-1.64B
-73.93%-555.84M
-100.62%-251.61M
-87.87%-319.58M
-125.42M
-170.11M
Basic earnings per share
95.83%-0.66
-38.33%-9.6
-404.46%-15.84
-73.93%-6.94
59.90%-3.14
67.13%-3.99
-7.83
-12.14
Diluted earnings per share
95.83%-0.66
-38.33%-9.6
-404.46%-15.84
-73.93%-6.94
59.90%-3.14
69.02%-3.99
-7.83
-12.88
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Auditor
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020
Turnover 178.30%95.58M1,110.83%137.62M5,119.30%34.34M457.70%11.37M313.84%658K--2.04M--159K----
Operating income 178.30%95.58M1,110.83%137.62M5,119.30%34.34M457.70%11.37M313.84%658K2.04M159K
Cost of sales -245.79%-45.24M-1,843.26%-66.62M-6,281.95%-13.08M-700.93%-3.43M-120.43%-205K---428K---93K----
Operating expenses -245.79%-45.24M-1,843.26%-66.62M-6,281.95%-13.08M-700.93%-3.43M-120.43%-205K-428K-93K
Gross profit 136.76%50.34M794.53%71.01M4,593.16%21.26M393.04%7.94M586.36%453K1.61M66K
Selling expenses -78.33%-103.49M-479.70%-208.31M-871.08%-58.03M-471.11%-35.93M-463.24%-5.98M---6.29M---1.06M----
Administrative expenses 23.12%-67.6M-85.05%-185.89M-113.71%-87.93M-55.15%-100.45M-30.43%-41.15M-131.96%-64.75M---31.55M---27.91M
Research and development expenses -9.84%-99.01M-19.34%-215.71M-8.00%-90.14M-63.49%-180.76M-66.46%-83.46M31.72%-110.56M---50.14M---161.93M
Revaluation surplus -----344.60%-1.45B-732.67%-1.45B-171.83%-327.1M-397.74%-174.65M-358.61%-120.33M---35.09M--46.53M
-Changes in the fair value of financial assets ---------------------------35.09M--46.53M
-Changes in the fair value of other assets -----344.60%-1.45B-732.67%-1.45B-171.83%-327.1M---174.65M---120.33M--------
Impairment and provision -------752K------------------------
-Other impairment is provision -------752K------------------------
Special items of operating profit -22.37%23.68M-57.84%34.65M-43.28%30.5M539.37%82.19M819.48%53.78M66.61%-18.71M---7.48M---56.02M
Operating profit 88.03%-196.08M-253.59%-1.96B-552.82%-1.64B-73.69%-554.11M-100.41%-251.01M-60.05%-319.02M-125.25M-199.33M
Financing cost -182.40%-4.85M-159.09%-4.48M-182.24%-1.72M-209.12%-1.73M-261.90%-608K6.68%-559K---168K---599K
Earning before tax 87.75%-200.93M-253.30%-1.96B-551.93%-1.64B-73.93%-555.84M-100.62%-251.61M-59.85%-319.58M-125.42M-199.93M
After-tax profit from continuing operations 87.75%-200.93M-253.30%-1.96B-551.93%-1.64B-73.93%-555.84M-100.62%-251.61M-59.85%-319.58M-125.42M-199.93M
Earning after tax 87.75%-200.93M-253.30%-1.96B-551.93%-1.64B-73.93%-555.84M-100.62%-251.61M-59.85%-319.58M-125.42M-199.93M
Minority profit -------------------------------29.82M
Profit attributable to shareholders 87.75%-200.93M-253.30%-1.96B-551.93%-1.64B-73.93%-555.84M-100.62%-251.61M-87.87%-319.58M-125.42M-170.11M
Basic earnings per share 95.83%-0.66-38.33%-9.6-404.46%-15.84-73.93%-6.9459.90%-3.1467.13%-3.99-7.83-12.14
Diluted earnings per share 95.83%-0.66-38.33%-9.6-404.46%-15.84-73.93%-6.9459.90%-3.1469.02%-3.99-7.83-12.88
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards IASIASIASIASIASIASIASIAS
Audit Opinions --Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion
Auditor --Ernst & Young--Ernst & Young--Ernst & Young--Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday-0.53%